Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP568 Monotherapy and Combination with Palbociclib in ER+/HER2- Advanced Breast Cancer
NCT06757335Phase 2Not yet recruiting
- Sponsor
- Hinova Pharmaceuticals Inc.
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
01
Overview
A Phase 2 trial of hp568 in hormone receptor-positive/HER2-negative breast cancer, sponsored by Hinova Pharmaceuticals Inc.. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
hp568
03
Conditions
hormone receptor-positive/HER2-negative breast cancer
Beyond the preview
Go deeper on NCT06757335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06757335.